Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis: Progress and Future Directions.

Abstract

Pulmonary lymphangioleiomyomatosis (LAM) is a rare genetic multisystem disease characterized by the nodular proliferation of smooth muscle-like LAM cells, progressive cystic changes of the lung, lymphatic abnormalities, and renal angiomyolipomas (AMLs). LAM can arise sporadically or in women with the autosomal dominant disorder, tuberous sclerosis complex (TSC), in which hamartomatous tumors of brain, heart, skin, kidney, and lung are found. LAM and TSC are caused by mutations in the TSC1 or TSC2 tumor suppressor genes leading to elevated mechanistic/mammalian target of rapamycin complex activity. Recent data indicate that T cells within LAM nodules and renal AMLs exhibit features of T-cell exhaustion, with coinhibitory receptor programmed cell death protein 1 (PD-1) expression on tumor-infiltrating T cells. Treatment of animal models of TSC and LAM with anti-PD-1 antibodies or with the combination of anti-PD-1 and anti-CTLA4 antibodies has led to remarkable results, suppressing TSC2-null tumor growth and inducing tumor rejection. Here we review our current knowledge about the potential for immunotherapy for the treatment of LAM and TSC and highlight critical unknowns and key next steps.

• Authors: Heng-Jia Liu, Vera P Krymskaya, Elizabeth P Henske
• Journal: Chest (Chest) Vol. 156 Issue 6 Pg. 1062-1067 (12 2019) ISSN: 1931-3543 [Electronic] United States
• PMID: 31437431 (Publication Type: Journal Article)
• Copyright: Copyright © 2019 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Topics

• Animals
• Cell Cycle Checkpoints (drug effects)
• Forecasting
• Humans
• Immunotherapy
• Lung Neoplasms (therapy)
• Lymphangioleiomyomatosis (therapy)
• Tuberous Sclerosis (therapy)